Molecular structure of Erlotinib Hydrochloride, CAS Number: 183319-69-9
Erlotinib Hydrochloride (CAS 183319-69-9)
See product citations (33)
Alternate Names:
Erlotinib Hydrochloride is known as a EGFR Kinase inhibitor.
Application:
Erlotinib Hydrochloride is a HER-1/EGFR tyrosine kinase inhibitor with anti-neoplastic properties, competitive with ATP.
CAS Number:
183319-69-9
Purity:
≥99%
Molecular Weight:
429.9
Molecular Formula:
C22H23N3O4•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Erlotinib hydrochloride is a compound widely studied in the context of cellular signaling and cancer research. It acts by inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase, an enzyme that plays a role in the signaling pathways influencing cell division and apoptosis. Scientists utilize this compound to dissect the intricacies of EGFR-related signaling cascades and to understand the resistance mechanisms that can arise with disrupted signaling in oncogenic cells. In materials science, its hydrochloride salt form offers enhanced solubility for in vitro assays. Additionally, the study of erlotinib hydrochloride in model cell lines provides insights into the molecular basis of kinase activity, assisting in the design of novel inhibitors that can modulate aberrant signaling in various cellular processes.
Erlotinib Hydrochloride (CAS 183319-69-9) References
- Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. | Chen, J., et al. 2007. Cancer Chemother Pharmacol. 59: 651-9. PMID: 16937104
- New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. | Burris, H. and Rocha-Lima, C. 2008. Oncologist. 13: 289-98. PMID: 18378539
- Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. | Ali, S., et al. 2008. Mol Cancer Ther. 7: 1708-19. PMID: 18566242
- Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin. | Rasoulzadeh, F., et al. 2010. Daru. 18: 179-84. PMID: 22615615
- Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. | Vrignaud, S., et al. 2012. Int J Pharm. 436: 194-200. PMID: 22721853
- Investigation on the site-selective binding of bovine serum albumin by erlotinib hydrochloride. | Liu, Y., et al. 2013. J Biomol Struct Dyn. 31: 1160-74. PMID: 23072300
- Modified synthesis of erlotinib hydrochloride. | Barghi, L., et al. 2012. Adv Pharm Bull. 2: 119-22. PMID: 24312780
- Development and application of an HPLC method for erlotinib protein binding studies. | Bolandnazar, S., et al. 2013. Adv Pharm Bull. 3: 289-93. PMID: 24312850
- Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. | Momin, MM., et al. 2018. Artif Cells Nanomed Biotechnol. 46: 1064-1075. PMID: 28758795
- Impaired Glycolysis Promotes AlcoholExposure-Induced Apoptosis in HEI-OC1 Cells via Inhibition of EGFR Signaling. | Kang, H., et al. 2020. Int J Mol Sci. 21: PMID: 31940844
- Chemosensitivity assessments of curdlan-doped smart nanocomposites containing erlotinib HCl. | Bera, H., et al. 2021. Int J Biol Macromol. 181: 169-179. PMID: 33775757
- Structural and functional changes of catalase through interaction with Erlotinib hydrochloride. Use of Chou's 5-steps rule to study mechanisms. | Shahraki, S., et al. 2021. Spectrochim Acta A Mol Biomol Spectrosc. 260: 119940. PMID: 34038867
- ST6Gal-I-mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion. | Rao, TC., et al. 2022. J Biol Chem. 298: 101726. PMID: 35157848
- Probing the combination of erlotinib hydrochloride, an anticancer drug, and human serum albumin: Spectroscopic, molecular docking, and molecular dynamic analyses. | Shahraki, S., et al. 2023. Luminescence.. PMID: 37060304
- Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. | Moyer, JD., et al. 1997. Cancer Res. 57: 4838-48. PMID: 9354447
Inhibitor of:
2700090O03Rik, 3Gn-T6, 3pK, 4930408F14Rik, 4933416I08Rik, 6720489N17Rik, 7530416G11Rik, 9330182O14Rik, ADCK5, AMPKα2, ARD1, ASPH, BinCARD, C20orf160, C6orf146, CD9P-1, CEACAM7, CLLD6, CNK1, CYP46, CYYR1, DAN, DNAJC25-GNG10, Dok-7, EF-CAB10, EG-VEGF, EGFL6, EGFR, Epiregulin, ESM-1, ETL, EVI2B, FAM75C2, Fes, GGH, Gm2897, Gm960, H2-22, HDGF, Kazrin, KNP-I, Lefty, LGALS9, LIN-3, LNP1, LOC388339, LTBP, MAGE-6, MAP17, MTERF, N-Shc, NBPF7, NET-4, NRIF2, Olfr1354, Olfr157, Olfr208, Olr1002, Olr104, Olr1052, Olr1060, Olr1065, Olr1111, Olr1199, Olr1203, Olr1225, Olr1235, Olr1257, Olr1286, Olr1293, Olr1295, Olr1307, Olr1320, Olr1321, Olr1323, Olr1330, Olr1331, Olr1334, Olr1383, Olr1384, Olr1398, Olr1561, Olr1576, Olr1622, Olr1646, Olr1718, Olr1733, Olr1748, Olr214, Olr235, Olr357, Olr375, Olr395, Olr440, Olr569, Olr727, Olr742, Olr748, Olr773, Olr775, Olr80, Olr81, Olr87, Olr879, Olr951, Olr956, Olr982, Olr996, PATE-G, PCDHB1, PCDHB2, PCDHGC, PERQ1, Pet117, PKR1, PL6, PRAMEF21, RASGEF1B, SCUBE1, Sdt, SERTM1, ST7L, STAM, TCP-c, TFIP11, TIGA1, TOB1, TPCN1, TRAAK, Trap1a, TREM-2b, UBAP1L, UNC5H2, UROC28, V1RD18, Vmn1r57, and Zfp804b.Activator of:
ADAM1, Capicua, DDEF2, M-Ras, MKP-7, PCDHA9, pki γ, raf-A, SPA-1, SPRED1, Testican-1, TIFAB, and XEDAR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Erlotinib Hydrochloride, 10 mg | sc-202154 | 10 mg | $74.00 | |||
Erlotinib Hydrochloride, 25 mg | sc-202154A | 25 mg | $119.00 |